Polski Bazalt Spółka Akcyjna (KRS 0000127342, NIP 9451925012) is a Polish company, headquartered in Radzymin, Mazowieckie voivodeship. Polski Bazalt operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since August 26, 2002.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Polski Bazalt
Identity
- Name
- Polski Bazalt Spółka Akcyjna
- Legal form
- SPÓŁKA AKCYJNA
- Founded
- August 26, 2002
- Registry status as of
- January 6, 2026
- Latest entry
- January 5, 2026
- Founding act
- - 28.08.2000 R. - NOTARIUSZ KONRAD WYGONA, KANCELARIA NOTARIALNA KRAKÓW, RYNEK GŁÓWNY 6, REP. A NR 3431/2000 - 08.04.200…
Articles of association history (6)
- August 28, 2000: - 28.08.2000 R. - NOTARIUSZ KONRAD WYGONA, KANCELARIA NOTARIALNA KRAKÓW, RYNEK GŁÓWNY 6, REP. A NR 3431/2000 - 08.04.2002 R. - NOTARIUSZ ROBERT LUDŹMIERSKI, KANCELARIA NOTARIALNA KRAKÓW, RYNEK GŁÓWNY GŁÓWNY 6, REP. A NR 3118/2002 ZMIANA: PAR. 5 UST.1; PAR. 7 UST. 1, 2, 3; PAR. 8 UST. 3; PAR. 9 UST. 1, 2, 3; PAR. 11; PAR. 13 UST. 1; PAR. 14 UST. 1 LIT. D, UST. 3; PAR. 16 UST. 6, 7; PAR. 17 UST. 4; PAR. 20 UST. 1; PAR. 21 UST. 1, 2 LIT. D PAR. 21 UST. 6; PAR. 22 UST. 3, 5, 6, 7, 9, 10, 11, 12; PAR. 23 LIT. A, C, G, J, Q; PAR. 24 UST. 1, 2, 3; PAR. 27 LIT. A, B; PAR. 25; PAR. 28; PAR. 29; PAR. 30; PAR. 32 LIT. B; PAR. 33; PAR. 35; PAR. 36 UST. 3; PAR. 37; PAR. 38; PAR. 40 SKREŚLA SIĘ: PAR. 7 UST. 9; PAR. 13 UST. 2; PAR. 35 ZD. II; PAR. 40 ZD. II DODAJE SIĘ: PAR. 9 UST. 4, 5, 6,; PAR. 10 UST. 3, 4; PAR. 16 UST. 11; PAR. 20 UST. 7; PAR. 21 UST. 2 LIT. J; PAR. 22 UST. 12, 13; PAR. 23 LIT. R
- June 2, 2003: 02.06.2003 ROK REP.A NR 1/2003 ROBERT LUDŹMIERSKI,KANCELARIA NOTARIALNA KRAKÓW UL.ŻÓŁKIEWSKIEGO 20: § 7 UST.1, § 7 UST.2, § 13-ZMIANA
- July 6, 2006: 06.07.2006 R. REP.A NR 10181/2006, NOTARIUSZ ROBERT LUDŹMIERSKI Z KANCELARII NOTARIALNEJ W KRAKOWIE ZMIANA:§ 1, § 5, § 7, § 8, § 9 UST.1, § 10 UST.2, § 11, § 14, § 15, § 16, § 17, § 20, § 21, § 22 UST.9, § 22 UST.11 SKREŚLONO:§ 23 LIT.R
- March 15, 2010: 15.03.2010 R. REP.A 413/2010 NOTARIUSZ TOMASZ OBTUŁOWICZ Z KANCELARII NOTARIALNEJ W KRAKOWIE ZMIANA § 5
- January 26, 2012: 26.01.2012 R.,REP.A NR 421/2012, NOTARIUSZ TOMASZ OBTUŁOWICZ, KANCELARIA NOTARIALNA W KRAKOWIE; ZMIANA §5 STATUTU SPÓŁKI
- September 7, 2018: AKT NOTARIALNY Z DNIA 07.09.2018R., REP. A NR 10675/2018 SPORZĄDZONY PRZEZ PAWŁA SAWICKIEGO-NOTARIUSZA W WARSZAWIE, PROWADZACEGO KANCELARIĘ NOTARIALNĄ W WARSZAWIE, UCHYLENIE DOTYCHCZASOWEJ TREŚCI STATUTU W CAŁOŚCI I PRZYJĘCIE TEKSTU JEDNOLITEGO STATUTU. SPROSTOWANIE AKT NOTARIALNY Z 12.10.2018, REP A NR 11754/2018 NOTARIUSZ PAWEŁ SAWICKI, KANCELARIA NOTARIALNA W WARSZAWIE SPROSTOWANIE AKT NOTARIALNY Z 29.10.2018R., REP A NR 12287/2018 NOTARIUSZPAWEŁ SAWICKI, KANCELARIA NOTARIALNA W WARSZAWIE
Activities
Other activities
Address and contact
- Address
- UL. WETERANÓW, 157, 05-250, RADZYMIN, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WOŁOMIŃSKI
- BIUROPOLSKIBAZALT@BAZALTHOLDING.PL
- Website
- HTTP://POLSKIBAZALT.PL/
- E-delivery address
- Not disclosed in the registry
Operational status - Polski Bazalt
Founded
August 26, 2002
23 years in operation
Legal form
SPÓŁKA AKCYJNA
Registry: RejP
Headquarters
RADZYMIN
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
761.8 K PLN
Shareholders
1
shareholder
Board
1 person
Registry entries
61
latest: January 5, 2026
No KPI data - financial statements and valuation are unavailable for this company.
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Polski Bazalt.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
